CRYOPORT, INC. Debt Instrument, Convertible, Conversion Ratio
CRYOPORT, INC. (CYRX) reported Debt Instrument, Convertible, Conversion Ratio of 13000.00% for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-04.
Discontinued › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentConvertibleConversionRatio1 · last filed 2021-11-04
- CRYOPORT, INC. debt instrument, convertible, conversion ratio for the quarter ending 2021-03-31 was 13000.00%.
- CRYOPORT, INC. debt instrument, convertible, conversion ratio for fiscal 2020 was 13000.00%.
| Period end | Debt Instrument, Convertible, Conversion Ratio 3 month | Debt Instrument, Convertible, Conversion Ratio 6 month | Debt Instrument, Convertible, Conversion Ratio 9 month | Debt Instrument, Convertible, Conversion Ratio 12 month |
|---|---|---|---|---|
| 2021-09-30 | 13000.00% 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | 13000.00% 10-Q · filed 2021-08-06 | |||
| 2021-03-31 | 13000.00% 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | 13000.00% 10-K · filed 2021-03-01 | |||
| 2020-09-30 | 4182.61% 10-Q · filed 2020-11-06 | |||
| 2020-06-30 | 4182.61% 10-Q · filed 2020-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |